top of page
The Professional Network for Healthcare Experts
AstraZeneca signs $1.5 billion AI drug discovery collaboration with insitro for cardiometabolic diseases
AstraZeneca and insitro have entered a $1.5 billion AI-enabled drug discovery collaboration targeting difficult-to-treat cardiometabolic diseases.
nuaxia
Oct 162 min read
GENFIT outlines $1.5bn US peak-sales opportunity for MASH diagnostics platform
GENFIT says its MASH diagnostics technology could support more than $1.5 billion in peak US sales by 2033 as the market for non-invasive patient identification expands.
nuaxia
Sep 101 min read
UK Expands Wegovy Approval to Include MASH Treatment
The MHRA has conditionally approved Novo Nordisk’s GLP-1 therapy for adults with metabolic-associated steatohepatitis, marking another milestone in the evolution of obesity medicines.
nuaxia
Jul 73 min read
bottom of page